And in my experience with complex patients, the mast cell, POTS, and chemically sensitive populations who cannot tolerate aggressive pharmaceutical interventions under any circumstances, this gentler approach has made GLP-1 therapy accessible to people who would have been completely excluded from it at standard doses
Results were even more compelling in the second trial, where patients were already utilizing PAP therapy
Excess weight, in and of itself, is not a disease. When it comes to her patients, she says, shes a stickler for a holistic approach to health, including eating a nutritious diet (not just eating less) and daily physical activity, as essential elements of the weight-loss process
But guarantees only matter if the company honors them quickly and consistently, with clear instructions and a reliable support channel
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study